Company
Company repositioned around cell therapy technologies and built an oncology pipeline
Every investor coverage indicates participated in a round Arovella Therapeutics raised.
Companies Arovella Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Arovella Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Arovella Therapeutics has produced its first clinical batch of ALA-101, a donor-derived cell therapy for blood cancer, and begun trials at a Melbourne hospital, with the first patient expected to be dosed this month.
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.